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ABSTRACT 
This paper deals with the various types of polymers, used in the 
fabrication of medical devices, their diversity of applications and toxic 
hazards which may arise out of their application. The potential toxicity 
of monomers and the various additives used in the manufacture of 
biomedical polymers have been discussed along with hazards which 
may arise out of processing of devices such as sterilization. The 
importance of quality control and stringent toxicity evaluation methods 
have been emphasised since in our country, at present, there are no 
regulations covering the manufacturing and marketing of medical 
devices. Finally the question of the general and subtle long term 
systemic toxicity of biomedical polymers have been brought to attention 
with the suggestion that this question needs to be resolved permanently , 
by appropriate studies. 
1. INTRODUCTION 
Man made replacements for broken or sick units of the human body was in the 
imagination of man in the past. This has given birth to a new branch of science, called 
'BIOMATERIAL SCIENCE'. This branch of science is interdisciplinary in nature and 
encompasses a variety of disciplines such as, Engineering, Physics, Chemistry, Biology, 
Toxicology, Biochemistry, Surgery, Dentistry. Metals, Ceramics, Polymers and 
Composite materials are used in the fabrication of medical devices. Their acceptance 
for use was partly through the time proven process of trial and,error than prior 
certification. This paper mainly deals with the use of polymers as medical devices and 
their potential health hazards. r 
Polymers in the form of elastomers and plastics have improved the quality of life 
over the last three decades. In 1855 Charles Goodyear detailed the use of gum-elastic 
for manufacturing irrigation syringes, hospital water beds, gloves etc. for medical 
use.' In this paper the discovery of vulcanization has been given. If we take 1855 as 
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the year of initiation of polymers into medicine, they have achieved tremendous 
diversity today in use and application. From simple disposable syringes and baby 
nursing nipples to artificial heart valves and total hip joint prosthesis are presently 
available in the market for medical use. Present day medical device industries are 
multimillion dollar projects with automated fabrication, quality control and packing 
facilities. Further, some of these factories have inhouse facilities for research and 
development to evolve better and newer formulations and designs. 
2. POLYMERIC MEDICAL DEVICES 
Polymeric devices that are being used in medical application can be broadly 
classified into five basic groups (Table 1). These devices have either direct or indirect 
contact with the body. 
Table 1. Classes of medid dedces and their possible potential hazards 
Class Device Examples Possible potential hazards 
1. OPemanent implants Heart valves, variousvascular Haemolysis, thrombosis, systemic 
grafts, orthopaedic implants, toxicity, allergy, carcino- 
other artificial internal organs genicity 
2. OImplants having Artificial eye, contact lens, Eyeltissue irritation, allergy, 
contact with mucosal dentures, intrauterine dwices, systeniic toxicity 
tissue certain type of catheters 
3. @Corrective, protective Splits, braces, films, Ti&ue initation, systemic toxicity, 
and supportive devices protective cloths etc haemolysis, allergy pyrogenicity 
4. @Collection adminis- Blood transfusion sets, various Tissue irritation, systemic toxicity, 
tration devices types of catheters, dialysing haemolysis, pyrogenicity , allergy 
units, hypodermic devices etc 
5. @Storage devices Containers, bags for blood, Haemolysis, systemic toxicity, 
blood products, drug products, pyrogenicity , allergy 
nutritional products, diagnostic 
agents etc 
Autian, J. Toxicology. IInd Ed. (Casaret and Poull's) Plastics. Page 534 (modified) 
0 Direct contact with the body 
Indirect wntact with the body 
All the polymers used in the fabrication of medical devices are not specifically 
compounded for clinical use. Two of the most prominent ones that are specifically 
manufactured for medical use are polyurethanes and silicone elastomers. These two 
groups of polymers appear to make use of the advances in plastic technology to 
produce purer polymers. In reality these two biomedical polymers are used in only a 
small fraction of the medical devices produced. A much larger volume of medical 
devices are manufactured from polymers that are made principally for other 
commercial applications in autoniobile industry, aerospace industry etc. Commonly 
used medical devices in which polymers are used and their approximate consumption 
is given in Table 2, 
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Table 2. Commonly used biomateW and W r  approxhnate consumption in an yesr 
Heart valves 60,000' 
Pace makers 100,000 
Vascular grafts 160,000 
Denturesldental devices 200,000 
Mammary glands/cosmetic replacements Wwoc' 
Nose 5,000 
Chin 3,000 
FaciaUdifferent places 6,000 
Testicles, penis 5,000 
Lenses 250,000 
Retinal surgical aids 500,000 
Other prosthesis lo,& 
Hip joint 110,000 
Knee point 70,000 
Other joints, splints, rods 150,000 
Oxygenators 200,000 
Accessories for open hearthypass surgery 210,000 
Renal dialiirs 620,000 
Prepared in 1982. Collected from various sources. 
Pure porymers themselves are of higher molecular weight and do not ;sually 
present a health hazard unless harmful chemical groups are attached to it. In the 
fabrication of plastic medical devices monomers are not the only raw materials but 
also substances like plasticizers, stabilizers, antioxidants, fillers, etc. are used to achieve 
the necessary physical and mechanical properties to the end product and for ease of 
fabrication. These intentionally added substances are collectively termed as additives. 
Polymeric materials that go into the fabrication of medical devices are foreign to 
the human body environment. These devices when come into contact with tissue may 
release one or more of their constituents causing local response at the site of contact. 
It is also possible that the leachants may get absorbed into circulation and may prodslce 
harmful effects on organs that are remotely placed. They may also initiate allergic 
responses, besides producing teratogenic, mutagenic and carcinogenic effects. Residual 
monomer if present in the finished medical device can pose a toxic hazard to the 
patient. Potential toxic contaminants may also get introduced into the product during 
processing, sterilization, packing, storage, transport etc. Though the majority of the 
polymeric medical devices are available in a fabricated final form, in certain cases the 
end product is formulated and polymerised just prior to being used. Surgical cements 
for orthopaedic use, adhesives and fillers far various dental applications etc. are some 
examples. Therefore, the toxicology ~f a polymeric medical device depends on the 
presence of residual monomer, e&ct of additive loss, degradation of plastics and the 
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effect of the degradation products, toxicity of leached additives and effect of 
sterilization methods on the nature of plastics or its constituents. 
3. RESIDUAL MONOMERS 
At the present time there is no evidence to indicate that a monomer such as vinyl 
chloride has caused cancer in clinical situation where PVC made devices have been 
in use. Nevertheless, from the occupational health hazard point of view, there is a 
serious implication here. Epidemiological surveys and monitoring of concentrations 
of vinyl monomer in the proximity of industries producing VC or PVC manufacturing 
plants in U.S.A. have shown that there is the hazard of liver cancer for people living 
around the plants handling large quantities of VC monomer. There is sufficient 
evidence that VC is a human carcinogen.' Its target organs are the liver (angiosarcoma), 
brain, lung and haemo- and lymphopoietic systems. Since there is no evidence that 
there is an exposure level below which no increased risk of cancer would occur in 
humans, various regulatory agencies in U.S.A. like the Food and Drug Administration, 
Bureau of Foods Occupational Safety and Health Agency (OSHA) etc. are constantly 
reviewing the standards for maximum permissible limits of the monomer and are 
aiming to obtain zero levels of the monomer content even in food packaging material.3 
Methyl methacrylate is the principal monomer used in the manufacture of acrylic 
polymers. In orthopaedic surgery, when an acrylic cement is prepared and used by 
the surgeon for anchoring hip prosthesis systemic toxicity has been observed in humans. 
Depending upon the nature of mixture, the quantity of monomer used and the insertion 
technique employed, sufficient free monomer may be released, which is absorbed by 
the blood stream leading to a dramatic drop in blood pressure and in some instances 
to death.3-6 Dentists may detect pulp toxicity, general irritation effects as well as 
hypersensitivity when various types of extemperaneously prepared acrylic adhesives, 
cements and filling materials were used in their patients7 
4. EFFECT OF ADDITIVE LOSS 
Cannulae, in particular, those made up of polyvinyl chloride could become hard 
because of the release of the additive plasticizer, leading to mechanical rigidity and 
irritation of the blood vessels or tissue in contact with the ~ a n n u l a e . ~  The tissue 
irritation was elicited by the leached out plasticizer. Tin stabilizers used in earlier 
PVC compositions also turned out to cause very strong tissue irritation leading to 
tissue necr~s i s .~  
5. POLYMER DEGRADATION 
When an implant polymer device is placed into a biological environment 
containing various cellular components and enzymes, it becomes very difficult to 
predict the fate of the implant. Polystyrene, polyethylene and polymethyl methacrylate 
polymers were radiolabelled and implantid in animals to study their in vivo 
degradation. With the above three plastics the degradation was faund to be very 
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slow.8 Polyamide and polyurethane plastics which are more hydrophilic than the above 
three plastics showed a more rapid rate of degradation. But, teflon, highly rated as 
an inert plastic when used in leaf type heart valves has broken and fragmented and 
caused embolism in coronary arterie~.~ It is also well known that, when nylon sutures 
and nylon vascular grafts were implanted in vivo, they became hard and later 
fragmented in some instances. The degradation processes of polymers and the fate 
sf such degradation products have been only poorly understood. 
6. TOXICITY OF ADDITIVES 
6.1 Plasticizers 
Plasticizers are added to a polymer to impart required flexibility. Polyvinyl 
chloride is the most widely used material in the manufacture of medical devices and 
about 70 per cent of the total annual production of plasticizers are used iq PVC items. 
Di-Zethyl hexyl phthalate (DEHP) is the most widely used plasticizer in medical PVC 
production and may comprise 30 or more per cent of a device by weight. Numerous 
studies have demonstrated that DEHP is extracted from PVC containers by saline, 
ACD solution, plasma-blood etc. stored in them. 
Jaeger and Rubin have shown that rate of DEHP accumulation in blood is 0.25 
mg/100 ml kg day over a period of 21 days storage in PVC bags.%I2 Studies carried 
out in patients who underwent multiple transfusions and involving cardiopulmonary 
bypass showed no DEHP in systemic cir~ulation'~~'~. But the same study showed 
significant levels of D m  in lung (91.5 pg/g dry weight), liver (69.5pg/g) and spleen 
(25.3 pglg). DEHP is also known to either depress or stimulate reticulo endothelial 
function, to increase the microaggregation of platelets in stored blood and to be lethal 
to 97 per cent of cultured chick heart cells at a concentration of only 4 pg/ml. In spite 
of large amount of experimental data, the subtle effects that may arise from the 
accumulation of minute quantities of DEHP in human tissue is still not understood. 
In recent studies significant evidence has been advanced for the carcinogenicity of 
DEHP in experimental animals2,15-'7. 
6.2 Stabilizers 
Polymers are susceptible to environmental degradation and effects of heat, light 
(ultraviolet) and oxygen are of particular importance. The manufacturing and 
preparatory process of most of the medical plastics involve heating in the presence 
of oxygen, then sterilization and exposure to light during transportation and storage. 
The degradation of a PVC device due to heat may yield HC1 from the polymer chain 
and if not prevented will continue the depolymerisation process. Stabilizers used to 
prevent this either &cept or scavenge the HC1 thereby blocking the propagation of 
the reaction. Organotins were used very effectively in early 1960 but when they were 
found out to be toxic to tissues their use in medical PVC was restricted. A large 
number of stabilizers have become available to replace organotin compounds. Calcium, 
magnesium and barium salts are being used singly or in combination. Various types 
of epoxies also are included in the stabilizing system. Toxicology data on most of the 
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stabilizers are either not available or incomplete. For those available, data on oral 
studies h e  bnly at hand. It is recommended that when more than one stabilizer is 
used, toxicity must be meas&ed by considering the combination rather than each 
agent alone, since a different synergistic effect could be the outcome very often7. 
6.3 Antioxidants 
These are included in the polymer formulation to inhibit the attack of oxygen 
during the processing and sterilization of the device. Oxidation normally proceeds by 
a free radical chain reaction. Free redicals present or generated within a polymer 
react with oxygen to form peroxy radicals which in turn may extract hydrogen atoms 
to form a hydroperoxide. Phenols, amines, sulfur or phosphate compounds are used 
as antioxidants depending on the free radicals expected to form. For many antioxidants 
toxicology data is available from feeding studies only. Chronic toxicity studies, using 
parenteral routes in animals have not been reported.7 
6.4 Fillers 
As in commercially used polymers medical polymers also contain fillers for 
economic reasons and for improving mechanical properties. Quartz, glass, silicates 
etc. are the common fillers used in medical polymers. These fillers are known to 
produce irritation to tissue and may act as allergens. A very good example of the 
imtant behaviour of filler is that of silica in medical grade silicone rubber. Asbestos 
fibres added as filler in peridental dressings have been noted to elicit marked epithelial 
damage.'* Toxicology data on commonly used fillers are incomplete and warrants 
further el~cidation.~ 
6.5 Catalysts 
Polymerization of a polymer is a chemical reaction and requires the presence of 
an initiator and naturally another agent to control the kinetics of polymerization and 
cross-linking if any. This is true for any device which is going to be a finished polymer 
device or on the spot mixed, cured and used polymer composite. Peroxides are very 
widely used for this purpose, especially benzoyl peroxides. Aliphatic azo compounds, 
titanium tetrachloride, boron trifluoride etc. are few examples of catalysts generally 
used. These are very reactive chemicals and are likely to be toxic. Catalysts are needed 
only in small quantities and for this reason the possibility of toxicity arising from them 
is low and therefore, not given much attention so far. 
6.6 Lubricants 
Lubricants are used.in the manufacturing process to decrease the viscosity of the 
resin metal friction during plastic processing. Lubricants also lower the die-swell of 
extruders and promotes surface gloss. Metallic stearates, waxes, fatty acids amides, 
fatty acids esters etc. are used as lubricants. Polyvinyl chloride is the major consumer 
of lubricants among polymer production. Recently, silicones,molybdenum salts and 
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polyflurocarbons are being used as lubricants during polymer production. When these 
agents are used for production, it becomes necessary to add additional chemical agents 
to prevent sticking of finished goods. These additional agents are known as 
anti-blocking agents. Data on the toxicity of agents used as lubricating and antiblocking 
agents are not available7. 
6.7 Blowing Agents 
Volatile fluorocarbons, methyl chloride, sodium bicarbonate, nitrogen, 
carbon-dioxide etc. are used as blowing agents in the manufacture of certain types 
polymer materials - when blow moulding techniques are employed. Studies on the 
presence of blowing agent residues in finished polymerdevices are not a~ailable.~ 
6.8 Flame Retardants 
Addition of flame retardant chemicals yield polymers that will not ignite or 
propagate flame readily and rapidly. Aluminium, antimony, boron, bromine, chlorine, 
molybdenum, nitrogen etc. are routinely used as flame retardants. Toxicity data on 
a number of these items are available though not with reference to medical device. 
Among the different polymers rigid PVC need not require addition of flame retardants 
because of its inherent chlorine content. But flexible PVC items however consume a 
good amount of flame retardant agents7. 
In the fabrication of medical device,colourants find only limited application. In 
the case of disposable plastics, especially containers, colour is used in connection with 
printing or labelling. Dyes and pigments are available in plastic industry as it is for 
textiles. Colour migration and bleeding are to be positively avoided in their application 
in medical polymers. Manufactures are required to use only approved colours. 
Toxicology of various dyes and colours worked out for use in food containers are 
available for referen~e.~ 
There are however other hazards that can arise due to treatment of a finished 
medical device, such as, sterilization. If ethylene oxide used for sterilization of 
polymeric devices is not desorbed properly it can produce irritation of tissues with 
which it may come into contact. It can also react with chlorides if present in the plastic 
surface, to produce ethylene chlorhydrin, a very toxic substance. A number of 
biomedical devices such as dialysis units are sterilized by the use of formaldehyde 
solution. This formaldehyde becomes sorbed to the plastic portions of the device and 
in turn can be released into blood or fluids which may come in contact with the 
device.19 Presence of residual glutaraldehyde used as a preservative and cross-linking 
agent for the small diameter synthetic vascular grafts was found in our own laboratories 
to give rise to Central Nervous System toxicity in e ~ r i m e n t a l  animakm Later it 
was found that adequate rinsing in sterile saline could solve this problem. 
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7. QUALITY CONTROL OF BIOMEDICAL DEVICES 
In the foregoing discussion, we have enumerated the various toxic health hazards 
that can be caused by polymers. This problem of toxicology of biomedical polymers 
assumes a specialsignificance since in our country medical devices are not subject to 
any kind of survelliance by regulatory agencies of the state or central government. 
The ingredient which go to make up the device are not also certified as fit for medical 
use. Under these circumstances, the onus of responsibility to make and market a safe 
medical device solely and unilaterally rests on the manufacturer. As pointed out earlier 
one has to choose the ingredients for a Biomedical polymer formulation from those 
that are generally marketed for non medical applications. It, therefore, becomes 
imperative to enforce thorough quality control checks on the raw materials (candidate 
materials) to ensure safety of the end product. It will be ideal to subject pre-shipment 
samples to appropriate chemical, physical, mechanical and toxicological tests 
(Table 3 & 4) to see whether they meet the established standards. Precautions must 
be taken to protect the hventoried co-polymer and other additives from moisture, 
heat aind contamination from other sources. It will be highly desirable to analyse the 
end product and gather data on the levels of residual monomers, oligomers, catalysts 
and other by-products, antioxidants, lubricants, slip agents etc. At present nothing is 
known about the presence of these low molecular weight species when in contact with 
body tissues. The user does not know the risks involved and has to passively ignore 
the consequences. The above mentioned data analysis will help the manufacturer to 
see that potential hazards, arising out of excessive levels of monomer residues, 
contaminants, low molecular wei&t additives etc. are avoided besides assuring that 
the physico-chemical and mechanical properties of the end product are in their limits 
of the safe functioning of the device. 
A note of caution may be made here regarding the reuse of disposable polymeric 
medical devices. For considerations of cost and lack of availability, there is a tendency 
in developing countries like ours to subject various polymeric disposable devices to 
repeated use. Even in economically advanced countries this practice is not uncommon. 
It is not possible to dwell at length tpe physiological, ethical and legal implications 
of reuse of disposable medical items in an article of this nature. There have been on 
record various adverse effects on patients resulting from this practice. To cite an 
example, a cardiac catheter broke and became lodged within the blood vessel of the 
patient's through. The catheter had been labelled by the manufacturer as being usable 
for a maximum of three times, whereas, in fact it had been used at least 19 times. 
An investigation which followed the incident revealed that 53 other catheters stocked 
in the hospital were being regularly reused eventhough some of them have never been 
resterili~ed.~' It will be, therefore, to the advantage of all concerned to adhere to the 
stipulations of the manufacturer in making effective use of disposable devices. 
8. CONCLUSION 
The more subtle and general issue of systemic effects of biomedical polymers 
need attentions. Polymeric implants can release compounds by structural degradation 
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Table 3. Surmnary of test procedures for biomedical materials 
Test Significance Standard test 
Physical Infra-red spectre 
SWPY 
Molecular structure and changes 
in chemical groups present. 
ASTM D1638-61T 
X-ray diffraction Crystalline structure 
Molecular weight Presence of low molecular weight 
fragments following deiyadation 
Melt index An indication of processability ; ASTM D120865T; 
ISOIR292 : 1967 empirical; not nicessarily related 
to biomedical applibtion 
Swelling index Related to structure and to in vivo 
swelling and ion permeabilitf 
O p t i d  plastics. Purity control 
BS 903 Part A16 
Refractive i n d e ~  
Mechanical Tensile properties Mechanical strenah and stiffness. 
Particularly valuable for weight 
bearing materials. Indicator of 
degradation. Use to find design 
accommodation of stresses 
within safe limits 
ASTM D63861T; ASTM 
D882-56T, BS2782-1965 
and PD5850m 6008,6269 
cover all tests; BS4077-1966 
(AMD65-1968); 




and flexural fatigue 
For cracking resistance and 
general deterioration after 
continuous flexion test 
Impact strength Toughness and impact rekistance. 
Useful for design. Indicates if 
sharp corners to be avoided. 
Minimal value but useful for 
comparisons of different grades 
ASTM D256-56; 
D1822-61- 
Isom180 : 1%1 
ASTM D695-63T; 




Stress relaxation Long-term dimensional changes 
in weight bearing application 
"Creep" 
. Abrasion resistance 
frictional and wear 
characteristics 
Where use in a moving surface 
is intended. 
ASTM D1242-56 
Chemical Hydrolytic resis- 
tance 
To determine possible biode- 
gradation resistance ahd products 
resulting from this. 
Extractability Shows up presence of soluble 
toxic ingredients 
Suitability of various 
methods in correlation with 
ASTM D1239-55, 
part 27,1965 
BS11333 sect 22 & 23 
refer to packaging 
Effects of 
sterilisation 
tensile tests, crystallinity by X-ray 




Determines effect of immersion 
in ahemical substances 
From : Plastic materials in surgery (Charles & Thomas), 1972. 
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Table 4. Toxicity screening protocol (general) 
1. Acute toxicity studies 
(a) In-situ implantation 
(b) Tissue culture 
(c) Haemolysis 
(d) Thrombogenicity 
(e) Systemic toxicity 
(f)  Imtation test 
2. Chronic toxicity studies 
(a) In-situ implantation 
(b) Systemic toxicity 




6. Special tests 
(a) Pyrogen test 
(b) Sterility test 
(c) Safety test 
(d) In-use test 
(depolymerisation and hydrolysis), elution or enzymatic attacks. These general 
systemic effects could be broadly classified as (i) carcinogenic effects, (ii) Metabolic 
effects, (iii) Bacteriologic effects and (iv) Immunologic effects. Very convincing 
arguments and evidence have been advanced to validate this concern over long term 
toxicity." The task, though colossal and daunting, must be taken up to resolve the 
issue in a satisfactory manner. 
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